121 related articles for article (PubMed ID: 3772420)
1. Etoposide pharmacokinetics in patients with normal and abnormal organ function.
Arbuck SG; Douglass HO; Crom WR; Goodwin P; Silk Y; Cooper C; Evans WE
J Clin Oncol; 1986 Nov; 4(11):1690-5. PubMed ID: 3772420
[TBL] [Abstract][Full Text] [Related]
2. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.
Stewart CF; Arbuck SG; Fleming RA; Evans WE
J Clin Oncol; 1990 Nov; 8(11):1874-9. PubMed ID: 2230875
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
4. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.
D'Incalci M; Rossi C; Zucchetti M; Urso R; Cavalli F; Mangioni C; Willems Y; Sessa C
Cancer Res; 1986 May; 46(5):2566-71. PubMed ID: 3697995
[TBL] [Abstract][Full Text] [Related]
6. Predicting etoposide toxicity: relationship to organ function and protein binding.
Joel SP; Shah R; Clark PI; Slevin ML
J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
[TBL] [Abstract][Full Text] [Related]
7. Etoposide kinetics in patients with obstructive jaundice.
Hande KR; Wolff SN; Greco FA; Hainsworth JD; Reed G; Johnson DH
J Clin Oncol; 1990 Jun; 8(6):1101-7. PubMed ID: 2348225
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
Minami H; Horio Y; Sakai S; Saka H; Shimokata K
Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
[TBL] [Abstract][Full Text] [Related]
9. Disposition of total and unbound etoposide following high-dose therapy.
Schwinghammer TL; Fleming RA; Rosenfeld CS; Przepiorka D; Shadduck RK; Bloom EJ; Stewart CF
Cancer Chemother Pharmacol; 1993; 32(4):273-8. PubMed ID: 8324869
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G
Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and pharmacokinetics of etoposide (VP-16).
Smyth RD; Pfeffer M; Scalzo A; Comis RL
Semin Oncol; 1985 Mar; 12(1 Suppl 2):48-51. PubMed ID: 3975657
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of high-dose melphalan in adults: influence of renal function.
Kergueris MF; Milpied N; Moreau P; Harousseau JL; Larousse C
Anticancer Res; 1994; 14(6A):2379-82. PubMed ID: 7825976
[TBL] [Abstract][Full Text] [Related]
14. Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.
Pflüger KH; Schmidt L; Merkel M; Jungclas H; Havemann K
Cancer Chemother Pharmacol; 1987; 20(1):59-66. PubMed ID: 3621455
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of high dose etoposide (VP 16-213).
Holthuis JJ; Postmus PE; Van Oort WJ; Hulshoff B; Verleun H; Sleijfer DT; Mulder NH
Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1149-55. PubMed ID: 3643849
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
Venook AP; Egorin MJ; Rosner GL; Brown TD; Jahan TM; Batist G; Hohl R; Budman D; Ratain MJ; Kearns CM; Schilsky RL
J Clin Oncol; 1998 May; 16(5):1811-9. PubMed ID: 9586895
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
[TBL] [Abstract][Full Text] [Related]
20. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]